Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 18, 2025 16:30 ET Â | Source: Ultragenyx Pharmaceutical Inc. NOVATO, Calif.,…
Ultragenyx Receives Complete Response Letter from FDA for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)
July 11, 2025 16:30 ET Â | Source: Ultragenyx Pharmaceutical Inc. Complete Response…